Evotec International GmbH has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.
Xinthera Inc. has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease, colitis, pouchitis, gastroenteritis, eosinophilic esophagitis and lung inflammatory disease.
